Our busy Media and PR Team provide journalists with the most
up-to-date and precise information on all aspects of prostate
cancer, as quickly as possible. We deliver expert responses to the
latest developments in prostate cancer research, as well as facts,
figures and spokespeople to guide you through the issues
surrounding the disease.
We also have access to around 150 people across the UK who have
been affected by prostate cancer, and are willing to share their
experiences with the media - our Media Talkers scheme.
In the Media Centre, you will find all our latest news releases
and comments, as well as the resources you need to shape an
article, including facts, statistics and profiles of our spokespeople. If you do need
any further information, you can also find the contact
details for the Media and PR Team who will be able to
Please note that the Media Centre is a tool for journalists. For
all other enquiries, please contact the Prostate Cancer UK
switchboard on 020 8222 7622.
Prostate Cancer UK (formerly The Prostate Cancer Charity) has welcomed the Scottish Medicines Consortium’s (SMC) decision to recommend abiraterone for use on the NHS in Scotland for men with incurable prostate cancer.
Researchers funded by Prostate Cancer UK and the Medical Research Council (MRC) have taken a crucial step forward by identifying a gene that’s potentially instrumental to the growth of both the prostate gland and prostate tumours. Scientists believe this discovery – published today in ‘PLOS ONE’ - could lead to improvements in prostate cancer diagnosis and treatment in the future.
Scotland “out on a limb” as Northern Ireland follows England & Wales in approving drug for NHS use.
Prostate Cancer UK (formerly The Prostate Cancer Charity) has renewed its call for the breakthrough prostate cancer drug abiraterone to be made available on the NHS in Scotland.